Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Accumulated Expenses (2021 - 2024)

Historic Accumulated Expenses for HCW Biologics (HCWB) over the last 4 years, with Q3 2024 value amounting to $90000.0.

  • HCW Biologics' Accumulated Expenses rose 1111.11% to $90000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $90000.0, marking a year-over-year increase of 1111.11%. This contributed to the annual value of $134000.0 for FY2022, which is N/A changed from last year.
  • As of Q3 2024, HCW Biologics' Accumulated Expenses stood at $90000.0, which was up 1111.11% from $152000.0 recorded in Q2 2024.
  • In the past 5 years, HCW Biologics' Accumulated Expenses ranged from a high of $240000.0 in Q3 2022 and a low of $53000.0 during Q1 2023
  • Its 4-year average for Accumulated Expenses is $141946.2, with a median of $134000.0 in 2022.
  • Per our database at Business Quant, HCW Biologics' Accumulated Expenses crashed by 7685.59% in 2023 and then soared by 9245.28% in 2024.
  • HCW Biologics' Accumulated Expenses (Quarter) stood at $214408.0 in 2021, then crashed by 37.5% to $134000.0 in 2022, then plummeted by 39.55% to $81000.0 in 2023, then increased by 11.11% to $90000.0 in 2024.
  • Its Accumulated Expenses was $90000.0 in Q3 2024, compared to $152000.0 in Q2 2024 and $102000.0 in Q1 2024.